Dr. Byrd on Updated RESONATE Findings in CLL

John C. Byrd, MD
Published: Wednesday, Aug 09, 2017



John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the updated findings of the RESONATE trial in chronic lymphocytic leukemia (CLL).

The RESONATE study is the first randomized phase III study that reported on the efficacy of the first-in-class irreversible inhibitor ibrutinib (Imbruvica), Byrd explains. This was a randomized trial that compared ibrutinib in second or greater line to ofatumumab (Arzerra), which was then the standard of care for patients with CLL. After it was clear that ibrutinib had significant activity, loss of equipoise existed for the control, and a crossover was allowed. At the 2017 ASCO Annual Meeting, long-term follow-up were presented at a median of 45 months for most patients and 4.5 years for some.

Results show that the updated overall response rate is currently 91%. There is a slight increase in complete remissions. The median progression-free survival at that median extended follow-up time still has not been reached for all genetic groups enrolled, though it appears that the 11q deletion group is performing the best, he adds.


John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the updated findings of the RESONATE trial in chronic lymphocytic leukemia (CLL).

The RESONATE study is the first randomized phase III study that reported on the efficacy of the first-in-class irreversible inhibitor ibrutinib (Imbruvica), Byrd explains. This was a randomized trial that compared ibrutinib in second or greater line to ofatumumab (Arzerra), which was then the standard of care for patients with CLL. After it was clear that ibrutinib had significant activity, loss of equipoise existed for the control, and a crossover was allowed. At the 2017 ASCO Annual Meeting, long-term follow-up were presented at a median of 45 months for most patients and 4.5 years for some.

Results show that the updated overall response rate is currently 91%. There is a slight increase in complete remissions. The median progression-free survival at that median extended follow-up time still has not been reached for all genetic groups enrolled, though it appears that the 11q deletion group is performing the best, he adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x